Phase
Condition
Prostate Cancer
Prostate Disorders
Prostate Cancer, Early, Recurrent
Treatment
N/AClinical Study ID
Ages > 18 Male
Study Summary
Eligibility Criteria
Inclusion
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the prostate
Clinical stage T1b-T3c disease
No clinical or radiographic evidence of metastasis
Prostate-specific antigen (PSA) less than 80 ng/mL
Gleason score at least 5
One of the following criteria must be met:
PSA greater than 10 ng/mL
Gleason score greater than 6
T2b or greater palpable disease
Three or more biopsy cores involved with a Gleason score of at least 5
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
No other medical condition that would preclude study participation
No other active malignancy within the past 5 years except nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic leukemia)
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
No more than 4 months of prior androgen deprivation therapy
Neoadjuvant and adjuvant androgen deprivation therapy is allowed for high-risk disease only
Radiotherapy
- No prior pelvic radiotherapy
Surgery
- No prior or planned radical prostate surgery
Study Design
Study Description
Connect with a study center
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania 19111-2497
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.